Understanding Cognition, Oxytocin & Pain in Elders

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

August 6, 2019

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions
Knee OsteoarthritisOsteoarthritis
Interventions
DRUG

Oxytocin (OT)

During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.

DRUG

Placebo (P)

During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.

Trial Locations (2)

32603

Department of Community Dentistry and Behavioral Science, Gainesville

32610

UF Health of University of Florida, Gainesville

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Florida

OTHER

NCT03878589 - Understanding Cognition, Oxytocin & Pain in Elders | Biotech Hunter | Biotech Hunter